Lentiviral Vector CDMOs with Clean FDA Inspection History
Lentiviral vectors are the workhorse of ex vivo gene therapy — used to engineer T cells for CAR-T, TCR programs, and to modify hematopoietic stem cells for inherited disorders. Because the vector integrates into the genome of patient-bound cells, lentiviral manufacturing carries the regulatory weight of a critical starting material under full GMP, mandatory replication-competent lentivirus (RCL) testing, and BSL-2 containment throughout production.
Selecting a lentiviral vector CDMO comes down to five buyer-critical dimensions: BSL-2 containment maturity and site inspection history on lentivirus specifically, a scalable suspension (or well-run adherent) platform, qualified titer + potency + RCL assays, capacity headroom at your target dose × patient volume, and defensible tech-transfer support. The rankings below score each CDMO on FDA inspection classifications, EMA/MHRA GMP density, ClinicalTrials.gov sponsor breadth, and monitored capacity signals — a composite that reflects the regulatory record and operational depth needed for material that lands in patient-bound cells.
FDA inspection outcomes across these CDMOs: 24 NAI (no action), 38 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (43), UNITED KINGDOM (38), Denmark (23), Germany (10), United Kingdom (7).
Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing all operator types.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
PB
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 5 insp · 1 GMP | 2026-08-14 · NAI | Available | — |
| 2 |
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
86.3 | 99.2 | 9 insp · 11 GMP | 2026-05-01 · NAI | Limited | — |
| 3 |
RP
Keele, UK · Sodertalje, SE
|
82.9 | 100.0 | 0 insp · 3 GMP | None on file | — | — |
| 4 |
BR
|
80.3 | 97.2 | 6 insp · 10 GMP | 2026-05-13 · VAI | — | — |
| 5 |
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
|
79.9 | 99.8 | 4 insp · 27 GMP | 2026-05-29 · NAI | Available | 2 programs |
| 6 |
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
|
79.5 | 100.0 | — | None on file | Available | — |
| 7 |
BV
|
79.4 | 99.8 | 1 insp · 4 GMP | 2024-12-19 · VAI | — | — |
| 8 |
GZ
|
78.1 | 100.0 | 1 insp · 0 GMP | 2025-08-27 · NAI | Available | — |
| 9 |
AA
Rockville, MD · Alachua, FL · Munich, DE
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 10 |
NG
Leiden, NL
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 11 |
ET
Jumet, BE
|
78.1 | 100.0 | 0 insp · 4 GMP | None on file | — | — |
| 12 |
PG
Berlin, DE
|
78.1 | 100.0 | 0 insp · 4 GMP | None on file | — | — |
| 13 |
AD
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 2 GMP | None on file | — | — |
| 14 |
TF
Plainville, MA · Alachua, FL · Cambridge, MA
Hiring · 299 open roles
Fully evidenced
|
77.6 | 93.2 | 19 insp · 10 GMP | 2026-06-30 · NAI | Available | 2 programs |
| 15 |
AG2
San Carlos, CA
|
77.6 | 98.8 | 1 insp · 0 GMP | 2025-04-18 · VAI | — | — |
| 16 |
OX
Oxford, United Kingdom
Hiring · 4 open roles
Fully evidenced
Also makes its own products
|
76.2 | 100.0 | 2 insp · 13 GMP | 2024-06-17 · NAI | Available | 7 programs |
| 17 |
CI
Cincinnati, OH
Hiring · 2 open roles
Fully evidenced
Academic / national centre
|
75.1 | 99.6 | 2 insp · 0 GMP | 2025-02-05 · NAI | — | 1 program |
| 18 |
NR
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Hiring · 100+ open roles
Fully evidenced
|
73.6 | 95.6 | 1 insp · 0 GMP | 2025-01-21 · VAI | Available | 9 programs |
| 19 |
|
72.8 | 86.6 | 11 insp · 8 GMP | 2025-09-29 · VAI | — | 1 program |